Lipoprotein(a), commonly abbreviated as Lp(a), is a specialized blood lipid component that represents a major independent risk factor for heart attacks, strokes, and other severe cardiovascular conditions. Approximately one in five people worldwide has elevated levels of Lp(a), a trait that is almost entirely inherited and remains largely unaffected by healthy diet, physical exercise, or traditional lipid-lowering therapies. Results from the international HORIZON study, co-authored by Prof. Dr. Ulf Landmesser from Deutsches Herzzentrum der Charité, have now been published, revealing that a targeted drug called Pelacarsen successfully lowered Lp(a) levels by nearly 80 percent but failed to prevent major cardiovascular events. The comprehensive findings were presented at the American Heart Association annual congress in Chicago and simultaneously published in the New England Journal of Medicine and NEJM Evidence.
Understanding Lp(a) and Its Role in Cardiovascular Risk

Lipoprotein(a) shares structural similarities with low-density lipoprotein, commonly known as LDL cholesterol. Both particles can easily penetrate the inner lining of blood vessels, contributing over time to the development of dangerous atherosclerotic plaques and narrowing of the arterial lumen. However, unlike LDL cholesterol, which can often be modified through dietary adjustments, exercise, and standard lipid-lowering medications, Lp(a) levels are determined almost exclusively by genetic inheritance from birth. Because elevated Lp(a) produces no obvious physical symptoms, many individuals remain unaware of their heightened risk until a severe vascular event occurs or detailed blood testing is performed.
High levels of Lp(a) significantly increase the long-term risk of developing coronary artery disease, ischemic strokes, peripheral artery disease, and aortic valve stenosis. In modern cardiovascular medicine, physicians focus on managing overall risk factors in affected individuals, such as lowering blood pressure and reducing LDL cholesterol levels as much as possible. Nevertheless, a specific, clinically proven medication capable of directly reducing Lp(a) to lower the rate of heart attacks has not been available in clinical practice. Developing a targeted pharmacologic intervention has therefore been a major scientific goal for cardiologists globally.
Pelacarsen was designed to address this therapeutic gap by interfering with the hepatic synthesis of Lp(a) particles at the molecular level. Researchers had anticipated that significantly reducing circulation levels of this specific lipid would directly translate into a lower incidence of life-threatening events in patients with established heart disease. However, human vascular biology has proven to be highly complex, demonstrating that reducing a specific circulating biomarker does not automatically eliminate established clinical risks in high-risk patient populations.
Key Findings from the International HORIZON Trial

The HORIZON study was a large-scale, randomized, double-blind clinical trial that enrolled 8,350 patients across 42 countries. All participants had pre-existing cardiovascular disease and elevated baseline levels of Lp(a). Patients received either monthly subcutaneous injections of Pelacarsen or a matching placebo formulation over an average follow-up period of 4.7 years. This extended observation timeframe allowed researchers to gather robust scientific data regarding the long-term safety and clinical efficacy of the treatment.
The trial results revealed that 12.3 percent of patients treated with Pelacarsen experienced a major adverse cardiovascular event, compared to 12.1 percent of patients in the placebo group. Despite achieving a average reduction in Lp(a) levels of approximately 78 percent within the first year of administration, Pelacarsen provided no statistically significant reduction in cardiovascular events. Further sub-analyses indicated that even participants with exceptionally high baseline Lp(a) levels experienced no measurable clinical benefit from the therapy.
The neutral outcomes surprised many experts in the field of preventive cardiology. Prof. Dr. Ulf Landmesser, Director of the Clinic for Cardiology, Angiology and Intensive Care Medicine at Campus Benjamin Franklin at Deutsches Herzzentrum der Charité, noted that these findings represent an important scientific milestone. He emphasized that while high Lp(a) levels are clearly linked to increased risk, significantly lowering the particle with this specific substance in patients with advanced vascular disease does not automatically prevent secondary clinical events.
Analyzing Biological Mechanisms and Tolerability Concerns

Commenting on the study outcomes, Prof. Dr. Ingo Hilgendorf from Campus Virchow-Klinikum at Deutsches Herzzentrum der Charité highlighted the exceptional scientific quality and rigorous design of the HORIZON trial. The study participants were already receiving optimal background therapy, with their LDL cholesterol and blood pressure levels well controlled according to modern clinical guidelines. Despite this comprehensive baseline management, more than twelve percent of participants suffered a subsequent major cardiovascular event, underscoring the significant residual risk present in this high-risk population.
Several hypotheses are currently being evaluated to explain why lowering Lp(a) failed to prevent clinical events in this study cohort. Because Lp(a) levels are elevated from birth, individuals with established cardiovascular disease have experienced decades of exposure to this lipoprotein. Lowering Lp(a) later in life, after advanced atherosclerotic plaque formation and structural vascular damage have already occurred, may offer limited additional clinical benefit. Researchers are considering whether therapeutic interventions targeting Lp(a) need to be initiated much earlier in life to prevent initial plaque formation.
Tolerability issues were also documented during the trial, with approximately 20 percent of participants in the Pelacarsen arm discontinuing treatment due to adverse events. The most common side effects reported were flu-like symptoms and localized injection site reactions. Furthermore, cardiologists emphasize that Lp(a) may contribute to vascular damage through multiple complex pathways beyond simple lipid accumulation, including localized vascular inflammation and increased blood clot formation, which may require multi-targeted therapeutic strategies.
Future Directions and Current Clinical Advice for Patients

The outcome of the HORIZON study does not mean the end of research into Lp(a)-lowering treatments. Alternative therapeutic approaches, such as small interfering RNA (siRNA) therapies, are currently being evaluated in major clinical trials. These newer agents have demonstrated the ability to reduce Lp(a) concentrations by over 90 percent and may offer improved tolerability profiles. Results from these ongoing outcome studies will be essential to determine whether different molecular mechanisms or greater degrees of Lp(a) suppression can effectively lower clinical event rates.
For patients seeking diagnostic evaluation and treatment in Germany, these findings reinforce the importance of comprehensive cardiovascular risk assessment. European professional guidelines continue to recommend that every adult should have their Lp(a) level measured at least once in their lifetime. Because standard blood cholesterol panels do not automatically include Lp(a) testing, patients should discuss specific testing with their physicians. Knowing one’s Lp(a) value allows cardiologists to better stratify individual risk and design targeted preventive care plans.
When elevated Lp(a) is identified, German cardiovascular specialists focus on aggressively managing all modifiable risk factors. This includes achieving optimal control of LDL cholesterol through modern pharmacotherapy, maintaining healthy blood pressure levels, managing blood glucose, and supporting smoking cessation. Leading heart centers in Germany, including Deutsches Herzzentrum der Charité, offer advanced diagnostic workups and personalized risk management protocols to protect vascular health even in the presence of inherited risk factors.